{"id":611921,"date":"2024-06-11T20:46:19","date_gmt":"2024-06-12T00:46:19","guid":{"rendered":"https:\/\/platohealth.ai\/former-fusion-cfo-crowley-joins-centessa\/"},"modified":"2024-06-12T05:35:23","modified_gmt":"2024-06-12T09:35:23","slug":"former-fusion-cfo-crowley-joins-centessa","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/former-fusion-cfo-crowley-joins-centessa\/","title":{"rendered":"Former Fusion CFO Crowley joins Centessa","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Management Tracks<\/p>\n

\n
\n
\n

Weinhoff becomes CBO. Plus: QurAlis pads C-suite and updates from PepGen, C4 and more<\/h2>\n

\n By Richard Guy, Biopharma Analyst, and Jeff Cranmer, Executive Editor<\/span><\/span>\n<\/p>\n

June 12, 2024 12:46 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

Days <\/span>after the completion of the takeout of his prior company, Fusion Pharmaceuticals Inc., John Crowley has become CFO of  Centessa Pharmaceuticals plc<\/a><\/b> (NASDAQ:CNTA). He succeeds Gregory Weinhoff, who takes on the newly created role of CBO. Crowley was CFO of Fusion until its $2 billion acquisition<\/a> by AstraZeneca plc (LSE:AZN; NASDAQ:AZN). <\/p>\n

Medicxi led the launch<\/a> of Centessa with $250 million in February 2021 to take asset-centric companies further. The biotech, which is led <\/span>by CEO Saurabh Saha, went public three months later in a $380 million IPO…<\/p>\n